Search Results

You are looking at 1 - 10 of 17 items for :

  • "meningiomas" x
  • By Author: Barnett, Gene H. x
Clear All
Restricted access

Gene H. Barnett, Russell W. Hardy Jr., John R. Little, Janet W. Bay and George W. Sypert

-convexity intracranial meningiomas, all of which had been successfully resected several years earlier. Neurological examination at that time was essentially normal except for mild spasticity of the right lower extremity. Radiological examination to evaluate the spasticity had revealed apophyseal hypertrophy of the lumbar spine with mild stenosis, as determined by computerized tomography (CT) sector scanning. Conservative therapy was recommended because it was thought that the mild spasticity could be explained as a residuum of the intracranial disease. The patient's complaints

Restricted access

Solitary fibrous tumor of the meninges

Case report and review of the literature

Richard A. Prayson, James T. McMahon and Gene H. Barnett

histologically malignant tumors died of tumor. Resectability appeared to be the single most important factor in predicting clinical outcome. Worrisome histological features, including nuclear pleomorphism and high mitotic rate, do not necessarily seem to be predictive of aggressive behavior if the tumor is circumscribed and amenable to complete excision. 3 The histopathological differential diagnosis of solitary fibrous tumor centers around other spindle cell neoplasms that arise in the meninges. The most notable differential diagnostic consideration is meningioma

Restricted access

Gene H. Barnett, David W. Miller and Joseph Weisenberger

diagnoses were made had subsequent clinical courses and radiological findings compatible with their histological diagnoses, according to our previous experience. 62 TABLE 1 Histological diagnoses of 218 brain biopsies obtained from 213 patients Diagnosis No. of Biopsies glioblastoma multiforme 60 anaplastic astrocytoma 22 metastases 20 low-grade astrocytoma 21 lymphoma 19 demyelinating disease 10 meningioma 10 nondiagnostic 8 low-grade oligodendroglioma 7 anaplastic oligodendroglioma 6 infarction 5 vasculitis 5 mixed glioma 4 abscess 3 juvenile pilocytic astrocytoma 2

Restricted access

Andrew A. Kanner, Michael A. Vogelbaum, Marc R. Mayberg, Joseph P. Weisenberger and Gene H. Barnett

(7.9)  lat 8 (12.7) procedure  craniotomy 31 (49.2)  awake craniotomy 7 (11.1)  biopsy 15 (23.8)  transsphenoidal 9 (14.3)  burr hole 1 (1.6) pathological finding  Grade III–IV glioma * 22 (34.9)  Grade II glioma * 16 (25.4)  pituitary adenoma 8 (12.7)  metastasis 4 (6.3)  meningioma 4 (6.3)  other † 9 (14.3) * World Health Organization grading. † Other cases included: two granulomas, one primary central nervous system lymphoma

Restricted access

Narendra Nathoo, Marc R. Mayberg and Gene H. Barnett

craniotomy. Unable to resist the opportunity to demonstrate his surgical skills, Gardner performed a large left-sided osteoplastic flap, removed a large globular meningioma, and finished the surgery in 2 hours and 20 minutes. With this display of his clinical acumen and surgical skill, the job was his with a salary of $6000 per year. 16 Luck was on Gardner's side; the stock market crashed 30 days later and the Great Depression began in the US. So began his career as Chief of Neurological Surgery at the Cleveland Clinic, an association that was to last for 33 years. After

Free access

Andrew E. Sloan, Manmeet S. Ahluwalia, Jose Valerio-Pascua, Sunil Manjila, Mark G. Torchia, Stephen E. Jones, Jeffrey L. Sunshine, Michael Phillips, Mark A. Griswold, Mark Clampitt, Cathy Brewer, Jennifer Jochum, Mary V. McGraw, Dawn Diorio, Gail Ditz and Gene H. Barnett

radiosurgery poses unacceptable risks or fails to rapidly reduce tumor mass effect. Although this study was limited to patients with rGBMs, NeuroBlate offers a potentially important method of intervention in patients with some low- to high-grade gliomas, whether benign or malignant, as well as benign tumors such as meningiomas, brain metastases, and failures of SRS for brain metastases. The NeuroBlate System received FDA 510(k) clearance on May 1, 2009. Clinical studies are planned or underway to further evaluate NeuroBlate for rGBMs as well as other malignant tumors and

Restricted access

Jason P. Sheehan, Robert M. Starke, David Mathieu, Byron Young, Penny K. Sneed, Veronica L. Chiang, John Y. K. Lee, Hideyuki Kano, Kyung-Jae Park, Ajay Niranjan, Douglas Kondziolka, Gene H. Barnett, Stephen Rush, John G. Golfinos and L. Dade Lunsford

after GKS for benign sellar and parasellar tumors. Similarly, in a group of patients with meningiomas of the cavernous sinus, improvements were noted in 29% of affected trigeminal nerves, 22% of CN III, and 13% of CNs IV and VI. 51 In the current study, CNs appeared to demonstrate a differential rate of impairment after GKS. Cranial nerve impairment in order of increasing frequency was as follows: CNs VII and IV; CN VI; CN V; CN III; and CN II ( Table 3 ). The risk of new or worsened optic neuropathy either from tumor growth or radiation injury was 6.6%. Although

Restricted access

Jaime Vengoechea, Andrew E. Sloan, Yanwen Chen, Xiaowei Guan, Quinn T. Ostrom, Amber Kerstetter, Devan Capella, Mark L. Cohen, Yingli Wolinsky, Karen Devine, Warren Selman, Gene H. Barnett, Ronald E. Warnick, Christopher McPherson, E. Antonio Chiocca, J. Bradley Elder and Jill S. Barnholtz-Sloan

M eningiomas account for 34% of all CNS tumors, with an estimated incidence of 6.59 per 100,000 in the US. 7 There is some controversy regarding the origin of meningiomas, but they appear to arise from the apex of arachnoid granulations in the meninges. 8 Meningiomas are classified according to the WHO grading system into Grade I, II, or III. Around 80% of meningiomas are benign, WHO Grade I tumors. 23 The prognosis for benign meningiomas is very good, but the 5-year survival for Grade II meningiomas is 79% and that of Grade III tumors is 53%. 9

Free access

Symeon Missios, Kimon Bekelis and Gene H. Barnett

. Eggert and Blazek 16 evaluated the optical properties of meninges, normal human brain tissue, and brain tumors at the spectral range between 200 and 900 nm. Within the visible and near-infrared spectral range, white matter showed the lowest level of absorption and the shortest penetration depth, low-grade gliomas revealed optical properties similar to those of gray matter, and meningiomas and glioblastomas showed significantly higher levels of absorption. The goal of LITT is to achieve selective thermal injury of pathological tissue while maintaining a sharp thermal

Restricted access

Jason P. Sheehan, Robert M. Starke, Hideyuki Kano, Gene H. Barnett, David Mathieu, Veronica Chiang, James B. Yu, Judith Hess, Heyoung L. McBride, Norissa Honea, Peter Nakaji, John Y. K. Lee, Gazanfar Rahmathulla, Wendi A. Evanoff, Michelle Alonso-Basanta and L. Dade Lunsford

O f all intracranial meningiomas, approximately 7%–12% are located in the posterior fossa. 13 , 16 , 56 Resection represents the upfront treatment for many patients with symptomatic or progressive posterior fossa meningiomas. 50 However, the extent of resection can be limited by the meningioma's proximity to critical vascular and neural structures. Gross-total resection rates reported in the literature for posterior fossa meningiomas vary significantly, from 40% to 96%, and resections are often associated with significant morbidity, mortality, and